Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment.
Bochicchio MT, Marconi G, Baldazzi C, Bandini L, Ruggieri F, Lucchesi A, Agostinelli C, Sabattini E, Orsatti A, Ferrari A, Capirossi G, Servili C, Ghelli Luserna di Rorà A, Martinelli G, Simonetti G, Rosti G. Bochicchio MT, et al. Among authors: ferrari a. Int J Mol Sci. 2023 Dec 21;25(1):118. doi: 10.3390/ijms25010118. Int J Mol Sci. 2023. PMID: 38203288 Free PMC article.
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia.
Bruno S, Bochicchio MT, Franchini E, Padella A, Marconi G, Ghelli Luserna di Rorà A, Venturi C, Raffini M, Prisinzano G, Ferrari A, Bandini L, Robustelli V, Pazzaglia M, Fontana MC, Sartor C, Abbenante MC, Papayannidis C, Soverini S, Ottaviani E, Simonetti G, Martinelli G. Bruno S, et al. Among authors: ferrari a. J Oncol. 2019 Oct 30;2019:5985923. doi: 10.1155/2019/5985923. eCollection 2019. J Oncol. 2019. PMID: 31827512 Free PMC article.
Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations.
Ferrari A, Cangini D, Ghelli Luserna di Rorà A, Condorelli A, Pugliese M, Schininà G, Cosentino S, Fonzi E, Domizio C, Simonetti G, Leotta S, Milone G, Martinelli G. Ferrari A, et al. Front Cell Dev Biol. 2023 May 23;11:1165308. doi: 10.3389/fcell.2023.1165308. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37287455 Free PMC article.
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway.
Padella A, Fontana MC, Marconi G, Fonzi E, Petracci E, Ferrari A, Baldazzi C, Papayannidis C, Ghelli Luserna Di Rorá A, Testoni N, Castellani G, Haferlach T, Martinelli G, Simonetti G. Padella A, et al. Among authors: ferrari a. Blood Cancer J. 2021 Jan 7;11(1):7. doi: 10.1038/s41408-020-00396-x. Blood Cancer J. 2021. PMID: 33414401 Free PMC article. No abstract available.
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.
Ghelli Luserna Di Rorà A, Beeharry N, Imbrogno E, Ferrari A, Robustelli V, Righi S, Sabattini E, Verga Falzacappa MV, Ronchini C, Testoni N, Baldazzi C, Papayannidis C, Abbenante MC, Marconi G, Paolini S, Parisi S, Sartor C, Fontana MC, De Matteis S, Iacobucci I, Pelicci PG, Cavo M, Yen TJ, Martinelli G. Ghelli Luserna Di Rorà A, et al. Among authors: ferrari a. J Hematol Oncol. 2018 Aug 1;11(1):99. doi: 10.1186/s13045-018-0641-1. J Hematol Oncol. 2018. PMID: 30068368 Free PMC article.
Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia.
Padella A, Simonetti G, Paciello G, Giotopoulos G, Baldazzi C, Righi S, Ghetti M, Stengel A, Guadagnuolo V, De Tommaso R, Papayannidis C, Robustelli V, Franchini E, Rorà AGLD, Ferrari A, Fontana MC, Bruno S, Ottaviani E, Soverini S, Storlazzi CT, Haferlach C, Sabattini E, Testoni N, Iacobucci I, Huntly BJP, Ficarra E, Martinelli G. Padella A, et al. Among authors: ferrari a. Cancers (Basel). 2019 Dec 5;11(12):1951. doi: 10.3390/cancers11121951. Cancers (Basel). 2019. PMID: 31817495 Free PMC article.
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
Ghelli Luserna Di Rorà A, Ghetti M, Ledda L, Ferrari A, Bocconcelli M, Padella A, Napolitano R, Fontana MC, Liverani C, Imbrogno E, Bochicchio MT, Paganelli M, Robustelli V, Sanogo S, Cerchione C, Fumagalli M, Rondoni M, Imovilli A, Musuraca G, Martinelli G, Simonetti G. Ghelli Luserna Di Rorà A, et al. Among authors: ferrari a. Cell Biol Toxicol. 2023 Jun;39(3):795-811. doi: 10.1007/s10565-021-09640-x. Epub 2021 Sep 14. Cell Biol Toxicol. 2023. PMID: 34519926 Free PMC article.
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
Derenzini E, Agostinelli C, Imbrogno E, Iacobucci I, Casadei B, Brighenti E, Righi S, Fuligni F, Ghelli Luserna Di Rorà A, Ferrari A, Martinelli G, Pileri S, Zinzani PL. Derenzini E, et al. Among authors: ferrari a. Oncotarget. 2015 Mar 30;6(9):6553-69. doi: 10.18632/oncotarget.2720. Oncotarget. 2015. PMID: 25544753 Free PMC article.
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.
Ghelli Luserna Di Rorà A, Iacobucci I, Imbrogno E, Papayannidis C, Derenzini E, Ferrari A, Guadagnuolo V, Robustelli V, Parisi S, Sartor C, Abbenante MC, Paolini S, Martinelli G. Ghelli Luserna Di Rorà A, et al. Among authors: ferrari a. Oncotarget. 2016 Aug 16;7(33):53377-53391. doi: 10.18632/oncotarget.10535. Oncotarget. 2016. PMID: 27438145 Free PMC article.
3,404 results